Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2).
OBJECTIVE
Photodynamic therapy (PDT) using a photoreactive purpurin, tin ethyl etiopurpurin (SnET2, Purlytin, Miravant Medical Technologies, Santa Barbara, CA), was investigated as a treatment for cutaneous metastatic disease that had failed other treatment options.


METHODS
Three patients with biopsy-proven metastatic adenocarcinoma of the skin were treated with a single dose of the study drug. Twenty-four hours later, the patients were exposed to a laser light at 664 nm in multiple light fields. Patients were followed for 6 months for safety, efficacy, recurrence, and palliative response.


RESULTS
After PDT with SnET2, complete response was observed in all 13 treated lesions in three patients, with no evidence of recurrence at any treated site at the 6-month follow-up. Two patients subsequently died of distant metastatic disease. One patient with local chest wall recurrence after mastectomy was disease-free 24 months after PDT.


CONCLUSIONS
PDT with SnET2 could be an effective treatment in locally advanced metastatic carcinoma of the skin.
Kaplan
M J
MJ
Department of Surgery, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141, USA.
Somers
R G
RG
Greenberg
R H
RH
Ackler
J
J
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010778:Photochemotherapy; D011166:Porphyrins / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D013365:Submandibular Gland Neoplasms / Q000473:pathology
D011166:Porphyrins; D011838:Radiation-Sensitizing Agents; C063166:tin etiopurpurin